Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer - PubMed (original) (raw)
Clinical Trial
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer
G Bolis et al. Gynecol Oncol. 2001 Apr.
Abstract
Objective: The aim of the study was to analyze the benefit/toxicity profile of a second-line treatment with carboplatin alone or carboplatin plus another non-cross-resistant drug (epidoxorubicin) in ovarian cancer patients sensitive to cisplatin-based chemotherapy at first-line treatment.
Methods: We conducted a randomized clinical trial. Women with epithelial ovarian cancer FIGO Stage II--IV who had a complete or partial response to first-line treatment with cisplatin or carboplatin-based regiments and subsequently progressed or relapsed more than 6 months after discontinuation of first-line treatment were eligible for the study. A total of 190 subjects entered the study. They were randomly allocated to either 300 mg/m(2) of carboplatin every 28 days for five cycles (95 patients) or 120 mg/m(2) of epidoxorubicin and 300 mg/m(2) of carboplatin every 28 days for five cycles (95 patients).
Results: A complete response was reported, respectively, in 32 (36%) women allocated to carboplatin alone and in 28 (31.8%) of those allocated to carboplatin plus epidoxorubicin. The corresponding figures for partial response were 18 (20.2%) and 26 (29.9%). Comparing the frequency of complete response, partial response, no change, and progression, the differences between the two groups were not significant (chi(2)(3) 5.10, P = 0.16). The median duration of response was 16 months in the carboplatin alone and 20 months in the carboplatin plus epidoxorubicin group (P = not significant). The 3-year percentage of survival was 29% in the carboplatin alone and 42% in the carboplatin plus epidoxorubicin group; this difference was not statistically significant. The frequency of leukopenia, anemia, and thrombocytopenia grade 3-4 was higher in the epidoxorubicin plus carboplatin than in the carboplatin alone group. Alopecia G3 was present in 88% of women treated with epidoxorubicin plus carboplatin.
Conclusions: The general results of this study do not show any marked differences in response to second-line treatment among women treated with single-agent (carboplatin) or multiagent (carboplatin plus epidoxorubicin) schedules. Toxicity, particularly hematological, was more relevant in women treated with the multiagent schedule.
Copyright 2001 Academic Press.
Comment in
- Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
Markman M. Markman M. Gynecol Oncol. 2001 Apr;81(1):1-2. doi: 10.1006/gyno.2001.6162. Gynecol Oncol. 2001. PMID: 11277641 Clinical Trial. No abstract available.
Similar articles
- Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.
Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Polatti A, Reina S, Pirletti E. Bolis G, et al. Gynecol Oncol. 1999 Jan;72(1):60-4. doi: 10.1006/gyno.1998.5237. Gynecol Oncol. 1999. PMID: 9889031 Clinical Trial. - Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G. Skarlos DV, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-57-S15-61. Semin Oncol. 1997. PMID: 9346224 Clinical Trial. - Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, Bruzzone M, Conte PF. Gadducci A, et al. Gynecol Oncol. 2000 Feb;76(2):157-62. doi: 10.1006/gyno.1999.5677. Gynecol Oncol. 2000. PMID: 10637064 Clinical Trial. - Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Colombo N, et al. Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review. - [Carboplatin in cancer of the ovary].
Pujade-Lauraine E, Guastalla JP, Vincent P. Pujade-Lauraine E, et al. Bull Cancer. 2000 Aug;87 Spec No:40-7. Bull Cancer. 2000. PMID: 11082722 Review. French.
Cited by
- Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer.
Coleman RL. Coleman RL. Curr Oncol Rep. 2007 Nov;9(6):469-71. doi: 10.1007/s11912-007-0065-5. Curr Oncol Rep. 2007. PMID: 17991354 No abstract available. - The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.
Bauerschlag DO, Schem C, Weigel MT, Von Kaisenberg C, Strauss A, Bauknecht T, Maass N, Meinhold-Heerlein I. Bauerschlag DO, et al. J Cancer Res Clin Oncol. 2010 Jan;136(1):79-88. doi: 10.1007/s00432-009-0639-8. J Cancer Res Clin Oncol. 2010. PMID: 19609560 - Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.
Elit L, Hirte H. Elit L, et al. Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26. Onco Targets Ther. 2013. PMID: 23459506 Free PMC article. - Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Fung-Kee-Fung M, et al. Curr Oncol. 2007 Oct;14(5):195-208. doi: 10.3747/co.2007.148. Curr Oncol. 2007. PMID: 17938703 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical